Taiwan’s Senhwa Biosciences Signs MOU to Advance AI-Related Drug Development

According to an April 14 report, the clinical-stage biopharmaceutical company in Taiwan partnered with a global investment group under a Memorandum of Understanding (non-binding preliminary agreement).

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.